Meir Wetzler

Medicine · Health Sciences

63h-index15.5kcitations384works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(199), Chronic Myeloid Leukemia Treatments(136), Acute Lymphoblastic Leukemia research(91), Chronic Lymphocytic Leukemia Research(91), Myeloproliferative Neoplasms: Diagnosis and Treatment(32)

Publications383 total

Supplementary Figure 3 from Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models
2023Open Access
Supplementary Figure 3 from Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models
2023Open Access
Supplementary Figure Legends from Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy <i>In vivo</i> in Human Acute Myeloid Leukemia Models
2023Open Access
Supplementary Figure 1 from Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models
2023Open Access
Data from Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models
2023Open Access
Data from Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models
2023Open Access
Supplementary Figures 7-8 from Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy <i>In vivo</i> in Human Acute Myeloid Leukemia Models
2023Open Access
Supplementary Tables 1-3 from Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy <i>In vivo</i> in Human Acute Myeloid Leukemia Models
2023Open Access
Supplementary Figure 2 from Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models
2023Open Access
Supplementary Figures 7-8 from Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy <i>In vivo</i> in Human Acute Myeloid Leukemia Models
2023Open Access
Supplementary Figure 5 from Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models
2023Open Access
Supplementary Figures 1-6 from Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy <i>In vivo</i> in Human Acute Myeloid Leukemia Models
2023Open Access
Supplementary Methods and References from Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy <i>In vivo</i> in Human Acute Myeloid Leukemia Models
2023Open Access
Data from Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy <i>In vivo</i> in Human Acute Myeloid Leukemia Models
2023Open Access
Data from Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy <i>In vivo</i> in Human Acute Myeloid Leukemia Models
2023Open Access
Supplementary Tables 1-3 from Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy <i>In vivo</i> in Human Acute Myeloid Leukemia Models
2023Open Access
Supplementary Methods and References from Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy <i>In vivo</i> in Human Acute Myeloid Leukemia Models
2023Open Access
Supplementary Figures 1-6 from Aflibercept Exerts Antivascular Effects and Enhances Levels of Anthracycline Chemotherapy <i>In vivo</i> in Human Acute Myeloid Leukemia Models
2023Open Access
Supplementary Figure 1 from Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models
2023Open Access
Supplementary Figure 2 from Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models
2023Open Access
page 1 of 20Next →

Frequent Co-authors

Maria R. Baer(16), Bayard L. Powell(15), Richard A. Larson(14), Clara D. Bloomfield(14), Krzysztof Mrózek(13), Guido Marcucci(12), Jonathan E. Kolitz(12), Andrew J. Carroll(12), Thomas H. Carter(10), Michael A. Caligiuri(10), Susan P. Whitman(9), Heiko Becker(9), Sebastian Schwind(9), Kati Maharry(8), Michael D. Radmacher(8), Moshe Talpaz(8), Yue-Zhong Wu(7), Klaus H. Metzeler(7), Razelle Kurzrock(7), Joseph O. Moore(6)